DOW JONES23,719.37+285.80 1.22%
S&P 5002,789.82+39.84 1.45%
NASDAQ8,153.58+62.67 0.77%

Nemaura To Prepare For Launch Of sugarBEAT CGM In The US Following FDA Feedback

Nemaura Medical Inc. (NASDAQ:NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing

Benzinga · 03/18/2020 11:07

Nemaura Medical Inc. (NASDAQ:NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor ("CGM"), together with BEAT®diabetes, a planned health subscription service designed to help people with Type 2 diabetes and pre-diabetes through personalized lifestyle coaching, announced it is preparing for the launch of sugarBEAT® in the U.S. under the wellness category following recent feedback from the U.S. Food and Drug Administration (the "FDA"). The Company is prioritizing launch plans in the U.S. and is considering various options to expedite the launch, including potential partnering in continuation of its on-going discussions with multi-national companies